• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    MorphoSys AG Form SC TO-T/Amended Shows Novartis BidCo AG Bought 2,023,370 Shares Of Common Stock Or About A 5.36% Stake; Highest Price Paid Was €67.95 Per Share

    4/15/24 3:55:01 PM ET
    $MOR
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MOR alert in real time by email

    On 11 April 2024, Novartis BidCo, Basel, Switzerland, ("Bidder") has published the offer document regarding its takeover offer (cash offer) to the shareholders of MorphoSys AG, Planegg, Germany ("MorphoSys") for the acquisition of all no-par value bearer shares (ISIN DE0006632003) ("MorphoSys Shares") including all no-par value bearer shares represented by American Depositary Shares (ISIN US6177602025) ("MorphoSys ADS") in MorphoSys against payment of a cash consideration in the amount of EUR 68.00 per MorphoSys Share. The acceptance period of the offer will expire on 13 May 2024, 24:00 hours (local time Frankfurt am Main, Germany) and 18:00 hours (local time New York, United States of America), unless it is extended pursuant to the applicable rules under the WpÜG.

     

    As of 12 April 2024 ("Reference Date"), i.e. after the publication of the offer document and prior to the publication pursuant to section 23 para. 1 sentence 1 no. 2 WpÜG, the Bidder acquired 2,023,370 MorphoSys Shares on the stock exchange. The highest price paid was EUR 67.95 per MorphoSys Share. The transfer of the 2,023,370 MorphoSys Shares to the Bidder is expected to take place within the next few days.

     

    The aggregate number of MorphoSys Shares for which purchase agreements were entered into on the Reference Date represents approx. 5.36 % of all MorphoSys Shares in existence on the Reference Date and approx. 5.37 % of all MorphoSys Shares in existence, other than treasury shares held by MorphoSys, on the Reference Date.

    Get the next $MOR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MOR
    $NVS

    CompanyDatePrice TargetRatingAnalyst
    Novartis AG
    $NVS
    3/11/2026$180.00Hold → Buy
    Argus
    Novartis AG
    $NVS
    1/27/2026Buy
    Citigroup
    Novartis AG
    $NVS
    1/6/2026Underweight → Equal Weight
    Barclays
    Novartis AG
    $NVS
    12/8/2025Neutral → Overweight
    Analyst
    Novartis AG
    $NVS
    12/3/2025Equal-Weight → Overweight
    Morgan Stanley
    Novartis AG
    $NVS
    11/25/2025Neutral → Buy
    BofA Securities
    Novartis AG
    $NVS
    9/12/2025$118.00Neutral → Sell
    Goldman
    Novartis AG
    $NVS
    8/8/2025$123.00Underweight → Equal-Weight
    Morgan Stanley
    More analyst ratings

    $MOR
    $NVS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 1, 2024 - FDA Roundup: November 1, 2024

    For Immediate Release: November 01, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “FDA Takes Exciting Steps Toward Establishing the Rare Disease Innovation Hub,” by Patrizia Cavazzoni, M.D., director of the FDA’s Center for Drug Evaluation and Research (CDER) and Peter Marks, M.D., Ph.D., director

    11/1/24 3:18:19 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MOR
    $NVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Novartis AG upgraded by Argus with a new price target

    Argus upgraded Novartis AG from Hold to Buy and set a new price target of $180.00

    3/11/26 8:29:46 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citigroup initiated coverage on Novartis AG

    Citigroup initiated coverage of Novartis AG with a rating of Buy

    1/27/26 8:47:55 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Novartis AG upgraded by Barclays

    Barclays upgraded Novartis AG from Underweight to Equal Weight

    1/6/26 1:39:21 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MOR
    $NVS
    SEC Filings

    View All

    SEC Form 6-K filed by Novartis AG

    6-K - NOVARTIS AG (0001114448) (Filer)

    3/18/26 4:23:38 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Novartis AG

    S-8 - NOVARTIS AG (0001114448) (Filer)

    2/4/26 4:30:35 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Novartis AG

    6-K - NOVARTIS AG (0001114448) (Filer)

    2/4/26 6:52:05 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MOR
    $NVS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

    Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar opportunities with planned product launches before 2030Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE:NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. ("Avidity"). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis. "Avidity's breakthrough science combined with

    2/27/26 9:00:00 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Salesforce's Agentforce Life Sciences Selected by Novartis to Drive More Personalized Customer Engagement Globally

    Salesforce (NYSE:CRM), the world's #1 AI CRM, announced today that Novartis (NYSE:NVS), a leading global innovative medicines company, has selected Salesforce's Agentforce Life Sciences for Customer Engagement to connect patient and healthcare professional (HCP) experiences, enabling teams to focus on strategic and meaningful customer interactions. Building upon its existing investments with Agentforce Health, Data 360 for Health & Life Sciences, MuleSoft for Life Sciences and Agentforce Marketing, Novartis plans to unify engagement across marketing, sales, patient services, medical, market access, and other service stakeholders to drive more cohesive, intelligent healthcare touchpoints. N

    12/17/25 9:00:00 AM ET
    $CRM
    $NVS
    Computer Software: Prepackaged Software
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Remeasuring Biotech Pipelines: The Valuation Signal Investors Have Been Waiting For

    AUSTIN, Texas, Nov. 20, 2025 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: As late-stage biotech pipelines mature, fair-value remeasurements under U.S. Generally Accepted Accounting Principles (GAAP) are emerging as critical indicators of tangible scientific and commercial progress. These revaluations provide a financial bridge between laboratory breakthroughs and shareholder value, offering investors a clearer picture of how innovation becomes measurable enterprise worth. Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile) exemplifies this shift as the company prepares for a significant fair-value remeasurement of its 45% stake in joint venture (JV) entity GMP Bio, driven by a new ind

    11/20/25 8:30:00 AM ET
    $BCAX
    $IOBT
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MOR
    $NVS
    Financials

    Live finance-specific insights

    View All

    Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

    Adds Avidity's differentiated muscle-directed Antibody Oligonucleotide Conjugates (AOC) platform and three late-stage programs to industry-leading neuromuscular pipelinePotentially unlocks multi-billion-dollar opportunities with planned product launches before 2030Strengthens late-stage pipeline to further support 2025-2030 net sales CAGR of 5-6% cc and mid to long term growth outlook Basel, February 27, 2026 -- Novartis AG (NYSE:NVS) today announced that it has successfully completed its acquisition of Avidity Biosciences, Inc. ("Avidity"). With the completion of the acquisition, Avidity is now an indirect, wholly owned subsidiary of Novartis. "Avidity's breakthrough science combined with

    2/27/26 9:00:00 AM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

    - PTC to receive $1.0B in cash at closing -- PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -- PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -- Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -- PTC will host a conference call on Dec. 2, 2024, at 8:30 am EST- WARREN, N.J., Dec. 2, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ:PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NY

    12/2/24 7:00:00 AM ET
    $NVS
    $PTCT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MorphoSys AG Reports First Quarter 2024 Financial Results

    – Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash, representing a total equity value of € 2.7 billion – Received all mandatory antitrust approvals for the proposed acquisition by Novartis – Shareholder acceptance period for the Novartis offer has commenced and will end on May 13, 2024, at 24:00 hours CEST – Sold all tafasitamab rights worldwide to Incyte – € 631.9 million in cash and other financial assets as of March 31, 2024 MorphoSys AG ((FSE: MOR, NASDAQ:MOR) reports results for the first quarter of 2024. "The proposed acquisition by Novartis is advancing steadily, and we continue to anticipate its closure in the first hal

    4/29/24 4:01:00 PM ET
    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MOR
    $NVS
    Leadership Updates

    Live Leadership Updates

    View All

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    PureTech Founded Entity Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. T

    11/5/24 7:05:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Seaport Therapeutics Names Lauren White as Chief Financial Officer

    Former ImmunoGen CFO will join Seaport to steer capital financing strategy, accounting, FP&A and investor relations Seaport Therapeutics ("Seaport or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the appointment of Lauren White as Chief Financial Officer. An accomplished biotech financial executive, Ms. White most recently served as the Chief Financial Officer at ImmunoGen (NASDAQ:IMGN) prior to its acquisition by AbbVie (NYSE:ABBV) for $10.1 billion in 2024. "I am so pleased to welcome Lauren as our CFO as we progress our clinical-stage pipeline of therapeutics for the treatme

    11/5/24 7:00:00 AM ET
    $ABBV
    $CCCC
    $IMGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $MOR
    $NVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Novartis AG

    SC 13D/A - NOVARTIS AG (0001114448) (Filed by)

    10/17/24 4:01:28 PM ET
    $NVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by MorphoSys AG

    SC 13D/A - MorphoSys AG (0001340243) (Subject)

    8/15/24 4:30:06 PM ET
    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by MorphoSys AG

    SC 13D/A - MorphoSys AG (0001340243) (Subject)

    6/21/24 4:30:07 PM ET
    $MOR
    Biotechnology: Pharmaceutical Preparations
    Health Care